文献速递系统性红斑狼疮其他结缔组织病

狼疮肾炎治疗1年时未达EULAR/ERA-EDTA缓解预测长期肾脏不良结局

Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis.
PubMed 文献 · Ann Rheum Dis · 2020-06-05

该研究纳入381例经肾活检并接受诱导治疗的狼疮肾炎患者,按EULAR/ERA-EDTA标准评估12个月缓解状态。中位随访10.7年期间53例发生CKD,12个月无缓解者15年无CKD生存率仅55.4%,多因素分析显示无缓解、低C4和持续高血压独立预测CKD。

要点

  • 12个月未达EULAR/ERA-EDTA缓解者15年无CKD生存率55.4%,显著低于完全或部分缓解者。
  • 完全缓解与部分缓解者CKD-free生存率无显著差异(p=0.067)。
  • 无缓解(HR 5.165)、低C4(HR 1.053)、持续高血压(HR 3.154)独立预测CKD。

核心结论

  • 狼疮肾炎患者治疗12个月时未达到EULAR/ERA-EDTA缓解可预测长期慢性肾脏病(CKD)发生。

研究设计与样本

  • 回顾性纳入1970年1月至2016年12月间经肾活检并接受诱导治疗的381例狼疮肾炎患者,90.5%为白种人。
  • 采用ISN/RPS(2003)标准及NIH活动性与慢性指数评估肾脏病理,以CKD为肾脏结局。
  • 12个月缓解按EULAR/ERA-EDTA标准分为完全、部分和无缓解,采用logistic回归分析12个月缓解、Cox回归预测CKD。

主要发现

  • 12个月治疗后58%达完全缓解、26%达部分缓解、16%无缓解。
  • 中位随访10.7年(IQR 4.97–18.80)期间53例发生CKD。
  • 15年无CKD生存率在完全、部分和无缓解者分别为95.2%、87.6%和55.4%(p<0.0001)。
  • 完全缓解与部分缓解者无CKD生存率无显著差异(p=0.067)。
  • 12个月血清肌酐(HR 1.485,95%CI 1.276–1.625)、eGFR(HR 0.967,95%CI 0.957–0.977)和蛋白尿(HR 1.234,95%CI 1.111–1.379)与CKD相关,但ROC曲线未确定可靠截断值。

关键数值与推荐

  • 完全缓解:蛋白尿<0.5 g/24h且eGFR(接近)正常;部分缓解:蛋白尿较基线下降≥50%至亚肾病水平且eGFR(接近)正常;无缓解:其余所有情况。
  • 多因素分析中12个月无EULAR/ERA-EDTA缓解(HR 5.165,95%CI 2.770–7.628)、低C4(HR 1.053,95%CI 1.019–1.089)、持续动脉高血压(HR 3.154,95%CI 1.500–4.547)独立预测CKD。

临床怎么用

  • 可将12个月时是否达到EULAR/ERA-EDTA缓解作为狼疮肾炎长期肾脏预后的早期预警指标。
  • 对12个月无缓解、低C4或持续高血压的狼疮肾炎患者应加强肾脏监测与干预。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Short-term predictive endpoints of chronic kidney disease (CKD) are needed in lupus nephritis (LN). We tested response to therapy at 1 year. METHODS: We considered patients with LN who underwent renal biopsy followed by induction therapy between January 1970 and December 2016. LN was assessed using the International Society of Nephrology/Renal Pathology Society (2003) criteria and the National Institute of Health (NIH) activity and chronicity index. The renal outcome was CKD. Response was defined according to EULAR/European League Against Rheumatism/European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations: complete: proteinuria <0.5 g/24 hours, (near) normal estimated glomerular filtration rate (eGFR); partial: ≥50% proteinuria reduction to subnephrotic levels, (near) normal eGFR; and no response: all the other cases. Logistic regression analysis was employed for 12-month response and Cox regression for CKD prediction. RESULTS: We studied 381 patients (90.5% Caucasians). After 12-month therapy, 58%, 26% and 16% of patients achieved complete, partial and no response, respectively, according to EULAR/ERA-EDTA. During a median follow-up of 10.7 (IQR: 4.97-18.80) years, 53 patients developed CKD. At 15 years, CKD-free survival rate was 95.2%, 87.6% and 55.4% in patients with complete, partial and no response at 12 months, respectively (p<0.0001). CKD-free survival rates did not differ between complete and partial responders (p=0.067). Serum creatinine (HR: 1.485, 95% CI 1.276 to 1.625), eGFR (HR 0.967, 95% CI 0.957 to 0.977) and proteinuria at 12 months (HR 1.234, 95% CI 1.111 to 1.379) were associated with CKD, yet no reliable cut-offs were identified on the receiver operating characteristic curve. In multivariable analysis, no EULAR/ERA-EDTA response at 12 months (HR 5.165, 95% CI 2.770 to 7.628), low C4 (HR 1.053, 95% CI 1.019 to 1.089) and persistent arterial hypertension (HR 3.154, 95% CI 1.500 to 4.547) independently predicted CKD. CONCLUSIONS: Lack of EULAR/ERA-EDTA response at 12 months predicts CKD.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Moroni G, Gatto M, Tamborini F, et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis. 2020. PMID: 32503858. doi:10.1136/annrheumdis-2020-216965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。